Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial.
Morgensztern D, Harb W, Schalper K, Price M, Early B, Schreiber T. Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial. Journal Of Clinical Oncology 2016, 34: tps9102-tps9102. DOI: 10.1200/jco.2016.34.15_suppl.tps9102.Peer-Reviewed Original Research